TY  - JOUR
AU  - Rosenstock, Julio
AU  - Sorli, Christopher H
AU  - Trautmann, Michael E
AU  - Morales, Cristóbal
AU  - Wendisch, Ulrich
AU  - Dailey, George
AU  - Hompesch, Marcus
AU  - Choi, In Young
AU  - Kang, Jahoon
AU  - Stewart, John
AU  - Yoon, Kun-Ho
PY  - 2019
DO  - 10.2337/dc18-2648
UR  - http://hdl.handle.net/10668/14260
T2  - Diabetes care
AB  - To explore the efficacy, safety, and tolerability of once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA), in early type 2 diabetes (T2D) (drug naive or on metformin monotherapy). EXCEED 203 was a 12-week,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Blood Glucose
KW  - Body Weight
KW  - Diabetes Mellitus, Type 2
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glucagon-Like Peptide-1 Receptor
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Liraglutide
KW  - Male
KW  - Metformin
KW  - Middle Aged
KW  - Proline
KW  - Treatment Outcome
TI  - Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
TY  - research article
VL  - 42
ER  -